Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab-Reference-Cited by-同舟云学术

Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab

Published:2018-06 Issue: Volume:95 Page:236-243
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Peraza Marjorie A.,Rule Karen E.,Shiue Michael H.I.,Finch Gregory L.,Thibault Stéphane,Brown Paul R.,Clarke David W.,Leach Michael W.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference30 articles.

1. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans;Bugelski;Curr. Opin. Mol. Ther.,2004

2. Waiving in vivo studies for monoclonal antibody biosimilar development: national and global challenges;Chapman;MAbs,2016

3. Sprague-Dawley Rats;Charles River Labs,2009

4. Nonclinical evaluation of PF-06438179: a potential biosimilar to Remicade® (infliximab);Derzi;Adv. Ther.,2016

5. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma;Ellis;Eur. J. Cancer,1998

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon‐regulatory factor‐1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14‐3‐3γ axis;ESC Heart Failure;2024-01-17

2. A Review of the Non-clinical and Clinical Requirements for the performance of a comparability exercise for Bevacizumab biosimilars;Research Journal of Pharmacy and Technology;2023-07-24

3. Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection;Journal of Ocular Pharmacology and Therapeutics;2023-04-01

4. Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr);Drugs in R&D;2023-02-22

5. Protein Therapeutics;Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology;2023